NCT06691412View on ClinicalTrials.gov

Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

March 1, 2026

Conditions
Hepatitis B VirusSteatosis
Interventions
DRUG

Obeticholic Acid 5 mg

\- Patients will be randomly divided into two groups , the first will receive obeticholic acid at a dose of 5 mg once daily and antiviral drug ,and the other will receive the antiviral drug only for six months

All Listed Sponsors
lead

Assiut University

OTHER

NCT06691412 - Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes | Biotech Hunter | Biotech Hunter